The generation of patient-derived hiPSCs provides a unique opportunity to gain a better understanding of variant-specific FGFR2-linked craniosynostosis at a molecular level in the patient-specific genomics context and illustrates the necessity for the development of personalized therapies. This evidence concerns the gene FGFR2 and craniosynostosis.